Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a... see more

TSX:SVA - Post Discussion

Sernova Corp > Smallcap stockpickig Canada
View:
Post by Charly50 on Dec 14, 2021 12:51pm

Smallcap stockpickig Canada

Top investor relations expert comes on board at Sernova
 
Finally. After a 6-month vacuum in the position, Sernova has hired a former investment banker (Vice President Institutional Sales at Octagon Capital, Vice President Institutional Sales at Fraser Mackenzie, Vice President Institutional Sales at an investment bank specializing in cleantech and ESG) as Vice President Investor Relations.
 
His network of institutional contacts (fund managers, asset managers, etc.) in Canada, the U.S., and Europe has already invigorated the Sernova share price in recent days.
 
He also has extensive investor relations expertise (ex-Director Investor Relations at Extendicare, a Canadian company that operates over 100 senior care facilities and had 2020 revenues of over 1.1 billion CAD).
Comment by MustangSalley on Dec 14, 2021 2:14pm
Charly , Look at his resume closely . He only lasts 1.5 years and then moves on . Longest tenure was 4 years and not even at a top tier company. He must be a Hollar and Matthews hand picked approval to be allowed on the inside circle of the boys club. They gave him a lot of options right of the get go before even seeing what he can do.  His LinkedIn is not impressive for the amount ...more  
Comment by BioTeck on Dec 14, 2021 3:31pm
The silver lining is that the stock price didn't crumble after the weak news. This guy looks like another Selphie. See him drinking beer in his LinkedIn picture? Total clown but perfect for the Sernova circus. The ringmaster is probably happy.
Comment by Metalsguy1 on Dec 14, 2021 3:50pm
My thoughts exactly BioTeck as soon as I saw his LinkedIn profile pic. Maybe he will be joining our Fraulein at a beer garden.
Comment by Redbaron2211 on Dec 14, 2021 9:53pm
We haven't had much luck in the past but there have definitely been a few big bids showing up out of the blue lately and unusual trading activity.  Correlation isn't causation but I will give him the benefit of the doubt for now and hope his network of institutional contacts will help bring in some big bags.
Comment by MustangSalley on Dec 14, 2021 10:38pm
You mean beer kegs? 
Comment by Redbaron2211 on Dec 14, 2021 11:56pm
haha hope not, I prefer champagne.  I'm sure it comes in a keg.  If the day ever comes its on me.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities